Urogen Pharma $URGN Shares Acquired by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lifted its holdings in Urogen Pharma (NASDAQ:URGN) by 50.8% during the second quarter, Holdings Channel reports. The institutional investor owned 276,696 shares of the company’s stock after purchasing an additional 93,192 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Urogen Pharma were worth $10,182,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. AQR Capital Management LLC lifted its holdings in Urogen Pharma by 347.5% in the first quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock valued at $1,262,000 after acquiring an additional 88,577 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Urogen Pharma by 7.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after purchasing an additional 1,653 shares during the period. Jane Street Group LLC grew its stake in shares of Urogen Pharma by 94.3% during the 1st quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock worth $566,000 after purchasing an additional 24,839 shares during the period. Cetera Investment Advisers purchased a new position in shares of Urogen Pharma in the 2nd quarter valued at about $361,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Urogen Pharma by 5.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 390,364 shares of the company’s stock valued at $5,348,000 after purchasing an additional 19,405 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

Urogen Pharma Price Performance

Shares of NASDAQ URGN opened at $46.96 on Friday. The firm’s 50-day moving average is $36.44 and its two-hundred day moving average is $27.12. The company has a market capitalization of $2.30 billion, a PE ratio of -23.72 and a beta of 1.57. Urogen Pharma has a 12-month low of $15.86 and a 12-month high of $48.19.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The firm had revenue of $72.46 million for the quarter, compared to analyst estimates of $63.55 million. On average, analysts forecast that Urogen Pharma will post -0.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on URGN. The Goldman Sachs Group reissued a “neutral” rating and set a $44.00 price objective on shares of Urogen Pharma in a report on Wednesday, July 15th. HC Wainwright boosted their price target on Urogen Pharma from $45.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a report on Friday, July 17th. Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. Finally, UBS Group reaffirmed a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $48.78.

More Urogen Pharma News

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: HC Wainwright significantly raised its FY2026 EPS forecast to a loss of $0.83 from a loss of $1.70. The firm also narrowed projected Q3 2026 and Q4 2026 losses to $0.07 and $0.01 per share, respectively. HC Wainwright FY2026 estimate update
• Positive Sentiment: The analyst now expects UroGen to reach profitability earlier than previously forecast, with estimates of $0.01 EPS in Q1 2027 and $0.17 EPS in Q2 2027, compared with prior loss estimates of $0.26 and $0.02 per share. HC Wainwright 2027 quarterly estimate update
• Positive Sentiment: HC Wainwright more than doubled its FY2027 EPS forecast to $1.05 from $0.50, while raising its Q3 2027 estimate to $0.36 from $0.28 and Q4 2027 to $0.50 from $0.49. These revisions strengthen the expected long-term earnings outlook. HC Wainwright FY2027 estimate update
• Neutral Sentiment: UroGen’s latest quarterly revenue of $72.46 million exceeded the $63.55 million consensus estimate, although its $0.28-per-share loss was slightly worse than the expected $0.26 loss. The mixed result makes the improved forward estimates particularly important to investors.

Insider Buying and Selling at Urogen Pharma

In other news, insider Mark Schoenberg sold 10,000 shares of the business’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the transaction, the insider directly owned 119,763 shares of the company’s stock, valued at $4,790,520. The trade was a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,222 shares of company stock valued at $892,661 over the last ninety days. Insiders own 4.80% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.